We are live on ! Find out more
EDIT icon

Editas Medicine

207 hedge funds and large institutions have $64.8M invested in Editas Medicine in 2024 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 61 increasing their positions, 56 reducing their positions, and 59 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 56

2% more call options, than puts

Call options by funds: $396K | Put options by funds: $388K

4.91% less ownership

Funds ownership: 66.76% → 61.84% (-4.9%)

10% less funds holding

Funds holding: 230 → 207 (-23)

41% less capital inflows, than outflows

Capital inflows: $27.5M | Capital outflows: $46.2M

56% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 59

Holders
207
Holders Change
-23
Holders Change %
-10%
% of All Funds
2.72%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
26
Increased
61
Reduced
56
Closed
59
Calls
$396​K
Puts
$388​K
Net Calls
+$8​K
Net Calls Change
-⁠$354​K

EDIT Hedge Fund Activity: Q4 2024 in Review

207 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q4 2024, worth a combined $64.8M — down 65% from $188M a quarter earlier.

Sellers outnumbered buyers: 59 funds closed out of EDIT and 26 opened new positions — a net loss of 33 holders — while 56 trimmed existing stakes and 61 added.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $3.7M. The largest seller was Deep Track Capital, exiting entirely with an estimated $16.7M sold.

  • 207 institutional investors held Editas Medicine (EDIT) as of Q4 2024, down from 230 in Q3 2024.
  • Funds reported $64.8M of Editas Medicine stock for Q4 2024, down 65% quarter-over-quarter.
  • 26 funds opened new Editas Medicine positions in Q4 2024 and 59 closed out, a net change of -33 holders.
  • The largest Editas Medicine buyer in Q4 2024 was Renaissance Technologies, an estimated $3.7M added.
  • The largest Editas Medicine seller in Q4 2024 was Deep Track Capital, an estimated $16.7M sold.

Based on aggregated 13F filings for Q4 2024.